major depressive disorder treatment

View All

Major Depressive Disorder Treatment
Long-Awaited Victory: Fabre-Kramer’s Major Depressive Disorder Treatment Drug Gains FDA Approval

Fabre-Kramer Pharmaceuticals’ major depressive disorder drug, gepirone, faced FDA rejection not once, not twice, but three times since the beginning of the 21st century. Finally, the company can rejoice as the FDA has granted long-awaited approval. On 29 September 2023, the FDA approved Fabre-Kramer Pharmaceuticals...

Find More

zuranolone-for-postpartum-depression-treatment
Mixed Fortunes for Biogen and Sage’ Zuranolone: Approval Under the Cloud of Rejection

In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting drug zuranolone as the first tablet for postpartum depression on 04 August —but rejected the drug for major depressive disorder treatment. Zurzuvae is a neuroactive steroid that acts as a GABA-A receptor-positive allosteric...

Find More

major-depressive-disorder-treatment-outlook
Will a Robust Pipeline Address the Major Depressive Disorder Treatment Conundrum?

In the contemporary world, major depressive disorder (MDD) is one of the diseases responsible for the greatest healthcare burden. In the United States, more than 24 million people suffer from major depressive disorder each year, while in Europe, about 20 million are diagnosed with the major depressive disorder each...

Find More